BioTuesdays

Giving great healthcare companies and their stories as much exposure as we can. Subscribe to our newsletter.

[BioTuesdays @BioTuesdays]

Stereotaxis has announced that it has submitted its robotically navigated catheter, EMAGIN 5F, for FDA regulatory clearance $STXS

https://t.co/EjX1jF1GjH

[BioTuesdays @BioTuesdays]

Personalis spotlights new publication from ICR and Royal Marsden on ctDNA testing in MRD $PSNL

https://t.co/iKcE9FLXYg

[BioTuesdays @BioTuesdays]

Medicus Pharma announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of the 60 patients targeted for enrollment $MDCX

https://t.co/OFkWgbU2EM

[BioTuesdays @BioTuesdays]

Biodexa Pharmaceuticals has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA $BDRX

https://t.co/ddz00fprU2

[BioTuesdays @BioTuesdays]

Esko Bionics names National Seating & Mobility as exclusive distributor of Ekso Indego Personal device within the complex rehabilitation technology industry $EKSO

https://t.co/Dk66lzNRxh

[BioTuesdays @BioTuesdays]

New data from BioRestorative Therapies’ ongoing Phase 2 trial of cell-based BRTX-100 in cLDD potentially show disc microenvironment remodeling in addition to reported improvements in VAS and ODI $BRTX

https://t.co/LWbeImf67H

[BioTuesdays @BioTuesdays]

In our latest #BioTuesdays feature, CEO Melissa Sherman, Ph.D., shares how @MobilionSystems, is redefining analytical characterization with next-gen separation science.

https://t.co/81nPBMgUkm

[BioTuesdays @BioTuesdays]

Therma Bright has announced the appointment of Steve Raysely to its advisory board $TBRIF

https://t.co/smP5hH7CZB

[BioTuesdays @BioTuesdays]

Tonix Pharmaceuticals has announced the appointment of Siobhan Fogarty as chief technical officer (CTO), effective immediately $TNXP

https://t.co/DnhLBeHYRh

[BioTuesdays @BioTuesdays]

INBS upgrades portable drug screening reader with multilingual capabilities $INBS

https://t.co/Trnm6d19kX

[BioTuesdays @BioTuesdays]

HOOKIPA Pharma has announced the completion of enrollment for its Phase 1b trial evaluating HB-500 in patients with HIV $HOOK

https://t.co/Xf2N0VT56h

[BioTuesdays @BioTuesdays]

Tectonic Therapeutic has announced positive interim data from its Phase 1b acute hemodynamic clinical trial of TX45 in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) $TECX

https://t.co/cmx80bI1bI

[BioTuesdays @BioTuesdays]

Polyrizon has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO) $PLRZ

https://t.co/dkOIeGMLAq

[BioTuesdays @BioTuesdays]

NLS Pharmaceutics has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence $NLSP

https://t.co/FMYfjTSN2a

[BioTuesdays @BioTuesdays]

Conduit Pharmaceuticals has announced that the first phase in its collaboration with Sarborg, aimed at integrating advanced AI and cybernetics technology into its operations has been completed $CDT

https://t.co/TwoQISEzLL

[BioTuesdays @BioTuesdays]

Stereotaxis has announced that it has received European CE Mark approval for its MAGIC ablation catheter, designed to perform cardiac ablation procedures aimed at treating heart arrhythmia $STXS

https://t.co/b0zezUvy1f

[BioTuesdays @BioTuesdays]

RenovoRX highlights abstract showcasing promising PK data for TAMP in LAPC $RNXT

https://t.co/PdiFtHtYQs

[BioTuesdays @BioTuesdays]

Veru has announced positive topline results from its Phase 2b QUALITY clinical study evaluating the safety and efficacy of enobosarm in patients receiving WEGOVY (semaglutide) for weight reduction $VERU

https://t.co/W7OHL9sagj

[BioTuesdays @BioTuesdays]

IPA (ImmunoPrecise Antibodies) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and obesity $IPA

https://t.co/10h1kZcseA

[BioTuesdays @BioTuesdays]

MeiraGTx has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD) by the FDA $MGTX

https://t.co/gXUygUTrsM